SEARCH

SEARCH BY CITATION

References

  • Barker, K.K. (2011). Listening to Lyrica: Contested illnesses and pharmaceutical determinism. Soc Sci Med 73, 833842.
  • Berger, A., Dukes, E., Martin, S., Edelsberg, J., Oster, G. (2007). Characteristics and healthcare costs of patients with fibromyalgia syndrome. Int J Clin Pract 61, 14981508.
  • Breivik, H., Collett, B., Ventafridda, V., Cohen, R., Gallacher, D. (2006). Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment. Eur J Pain 10, 287333.
  • Briley, M. (2009). Drugs to treat fibromyalgia – the transatlantic difference. Curr Opin Investig Drugs 11, 1618.
  • Chappell, A.S., Littlejohn, G., Kajdasz, D.K., Scheinberg, M., D'Souza, D.N., Moldofsky, H. (2009). A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia. Clin J Pain 25, 365375.
  • Cohen, J. (1988). Statistical Power Analysis for the Behavioral Sciences (Hillsdale: Lawrence Erlbaum).
  • Corporation, S. (2011). Stata Statistical Software: Release 12.0 (College Station, TX: Stata Corporation).
  • Hauser, W., Petzke, F., Sommer, C. (2010a). Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. J Pain 11, 505521.
  • Hauser, W., Thieme, K., Turk, D.C. (2010b). Guidelines on the management of fibromyalgia syndrome – a systematic review. Eur J Pain 14, 510.
  • Häuser, W., Petzke, F., Üçeyler, N., Sommer, C. (2011). Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: A systematic review with meta-analysis. Rheumatology 50, 532.
  • Mease, P.J., Russell, I.J., Kajdasz, D.K., Wiltse, C.G., Detke, M.J., Wohlreich, M.M., Walker, D.J., Chappell, A.S. (2009). Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia. Semin Arthritis Rheum 39, 454464.
  • Murphy, K., Zeiher, B., Herman, B., Atkinson, G., Pauer, L., Whelan, L. (2009). Long-term safety and tolerability of pregabalin treatment in three open-label extension studies in patients with fibromyalgia. J Pain 10, S58S58.
  • Taylor, G., Wainwright, P. (2005). Open label extension studies: Research or marketing? BMJ 331, 572.
  • Wolfe, F., Hassett, A.F., Katz, R.S., Michaud, K. (2011). Do we need core sets of fibromyalgia domains? The assessment of fibromyalgia (and other rheumatic disorders) in clinical practice. J Rheumatol 38, 11041112.
  • Wolfe, F., Michaud, K. (2010a). The Hawthorne effect, sponsored trials, and the overestimation of treatment effectiveness. J Rheumatol 37, 2216.
  • Wolfe, F., Michaud, K. (2010b). Themed issues 2010: The National Data Bank for Rheumatic Diseases (NDB): A multi-registry rheumatic disease data bank. Rheumatology (Oxford) 50, 1624.